Open AccessErratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026–2035
Author(s) -
Julio Rosenstock,
Ronnie Aronson,
George Grunberger,
M Hanefeld,
PierMarco Piatti,
Pierre Sérusclat,
Xi Cheng,
Tianyue Zhou,
Elisabeth Niemoeller,
Elisabeth Souhami,
Melanie J. Davies
Publication year - 2017
Publication title -
diabetes care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.636
H-Index - 363
eISSN - 1935-5548
pISSN - 0149-5992
DOI - 10.2337/dc17-er06c
Subject(s) - medicine , lixisenatide , insulin glargine , type 2 diabetes , diabetes mellitus , endocrinology , pharmacology , basal insulin
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom